AVX Pharma   Report issue

For profit Phase 2
Founded: Barcelona Spain (2013)
Status: Acquired by Aerie Pharmaceuticals (2019) → now Novartis (2022)

Organization Overview

First Clinical Trial
2017
NCT03162094
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

avx012 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dry Eye Syndromes (Phase 2)

Keratoconjunctivitis Sicca (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1